Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 2/20 | 0.52 |
| ▸ | CDK4 | P11802 | 2/20 | 0.52 |
| ▸ | CCND1 | P24385 | 2/20 | 0.52 |
| ▸ | CCND3 | P30281 | 2/20 | 0.52 |
| ▸ | CDK9 | P50750 | 2/20 | 0.52 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.52 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.52 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | CCNH | P51946 | 1/20 | 0.35 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20956353 | 0.80 | CDK4 (0.50) | CCNT1CDK4CCND1CCND3CDK9 | |
| SCHEMBL19402045 | 0.79 | CDK4 (0.48) | CCNT1CDK4CCND1CCND3CDK9 | |
| SCHEMBL20956346 | 0.75 | CDK4 (0.35) | CCNT1CDK4CCND1CCND3CDK9 | |
| SCHEMBL20677023 | 0.70 | CDK4 (0.35) | CCNT1CDK4CCND1CCND3CDK9 | |
| SCHEMBL20956368 | 0.69 | EIF2AK4 (0.36) | CCNT1CDK4CCND1CCND3CDK9 | |
| SCHEMBL20956374 | 0.69 | CCND3 (0.54) | CCNT1CDK4CCND1CCND3CDK9 | |
| SCHEMBL14846570 | 0.68 | IDH1 (0.56) | — | |
| SCHEMBL20991838 | 0.67 | CCNT1 (0.48) | CCNT1CDK4CCND1CCND3CDK9 | |
| SCHEMBL22414135 | 0.67 | CDK4 (0.50) | CDK4CCND1CCND3CDK6TRPV1 | |
| SCHEMBL20956355 | 0.67 | CDK4 (0.39) | CCNT1CDK4CCND1CCND3CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020206034-A1 | CELL CYCLE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20200283406-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | G1 THERAPEUTICS, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200283406-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | G1 THERAPEUTICS, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-10654831-B2 | Antiproliferative pyrimidine-based compounds | G1 THERAPEUTICS, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-10654831-B2 | Antiproliferative pyrimidine-based compounds | G1 THERAPEUTICS, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190135784-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190135784-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135784-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | MKI67, TYMS, TYMP | CCNT1 72/4885CDK4 40/4885CCND1 63/4885 |
| US-10654831-B2 | Antiproliferative pyrimidine-based compounds | MKI67, TYMS, TYMP | CCNT1 72/4885CDK4 40/4885CCND1 63/4885 |
| US-20200283406-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | MKI67, TYMS, TYMP | CCNT1 72/4885CDK4 40/4885CCND1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.